Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

NCT00294762 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

143

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Tarceva
DRUG: carboplatin
DRUG: paclitaxel

Sponsor

OSI Pharmaceuticals